Logo image of FTRE

FORTREA HOLDINGS INC (FTRE) Stock Fundamental Analysis

NASDAQ:FTRE - Nasdaq - US34965K1079 - Common Stock - Currency: USD

4.5901  -0.1 (-2.13%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to FTRE. FTRE was compared to 54 industry peers in the Life Sciences Tools & Services industry. FTRE has a bad profitability rating. Also its financial health evaluation is rather negative. FTRE is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FTRE was profitable.
In the past year FTRE had a positive cash flow from operations.
In multiple years FTRE reported negative net income over the last 5 years.
FTRE had a positive operating cash flow in each of the past 5 years.
FTRE Yearly Net Income VS EBIT VS OCF VS FCFFTRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

FTRE has a Return On Assets of -25.32%. This is in the lower half of the industry: FTRE underperforms 72.22% of its industry peers.
The Return On Equity of FTRE (-92.04%) is worse than 77.78% of its industry peers.
Industry RankSector Rank
ROA -25.32%
ROE -92.04%
ROIC N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
FTRE Yearly ROA, ROE, ROICFTRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

FTRE has a worse Gross Margin (20.21%) than 81.48% of its industry peers.
FTRE's Gross Margin has been stable in the last couple of years.
FTRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
FTRE Yearly Profit, Operating, Gross MarginsFTRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

1

2. Health

2.1 Basic Checks

FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
FTRE has more shares outstanding than it did 1 year ago.
The debt/assets ratio for FTRE has been reduced compared to a year ago.
FTRE Yearly Shares OutstandingFTRE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
FTRE Yearly Total Debt VS Total AssetsFTRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

FTRE has an Altman-Z score of 0.42. This is a bad value and indicates that FTRE is not financially healthy and even has some risk of bankruptcy.
FTRE has a worse Altman-Z score (0.42) than 70.37% of its industry peers.
The Debt to FCF ratio of FTRE is 8.36, which is on the high side as it means it would take FTRE, 8.36 years of fcf income to pay off all of its debts.
FTRE has a Debt to FCF ratio (8.36) which is in line with its industry peers.
FTRE has a Debt/Equity ratio of 1.22. This is a high value indicating a heavy dependency on external financing.
FTRE has a Debt to Equity ratio of 1.22. This is amonst the worse of the industry: FTRE underperforms 83.33% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF 8.36
Altman-Z 0.42
ROIC/WACCN/A
WACC6.83%
FTRE Yearly LT Debt VS Equity VS FCFFTRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

A Current Ratio of 0.97 indicates that FTRE may have some problems paying its short term obligations.
FTRE has a worse Current ratio (0.97) than 88.89% of its industry peers.
FTRE has a Quick Ratio of 0.97. This is a bad value and indicates that FTRE is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.97, FTRE is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.97
FTRE Yearly Current Assets VS Current LiabilitesFTRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

FTRE shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -543.42%.
Looking at the last year, FTRE shows a very negative growth in Revenue. The Revenue has decreased by -10.69% in the last year.
The Revenue has been decreasing by -4.10% on average over the past years.
EPS 1Y (TTM)-543.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)-10.69%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%-1.63%

3.2 Future

The Earnings Per Share is expected to grow by 41.59% on average over the next years. This is a very strong growth
Based on estimates for the next years, FTRE will show a small growth in Revenue. The Revenue will grow by 1.93% on average per year.
EPS Next Y40.94%
EPS Next 2Y52.2%
EPS Next 3Y46.84%
EPS Next 5Y41.59%
Revenue Next Year-6.93%
Revenue Next 2Y-3.07%
Revenue Next 3Y-0.94%
Revenue Next 5Y1.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FTRE Yearly Revenue VS EstimatesFTRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
FTRE Yearly EPS VS EstimatesFTRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 11.48 indicates a reasonable valuation of FTRE.
Based on the Price/Earnings ratio, FTRE is valued cheaper than 98.15% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.54, FTRE is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 5.83, the valuation of FTRE can be described as very cheap.
Based on the Price/Forward Earnings ratio, FTRE is valued cheaply inside the industry as 98.15% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 36.44. FTRE is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 11.48
Fwd PE 5.83
FTRE Price Earnings VS Forward Price EarningsFTRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

FTRE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FTRE is cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.86
EV/EBITDA N/A
FTRE Per share dataFTRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FTRE's earnings are expected to grow with 46.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.28
PEG (5Y)N/A
EPS Next 2Y52.2%
EPS Next 3Y46.84%

More info and screens

0

5. Dividend

5.1 Amount

FTRE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTREA HOLDINGS INC

NASDAQ:FTRE (7/21/2025, 12:06:22 PM)

4.5901

-0.1 (-2.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners102.48%
Inst Owner Change-0.82%
Ins Owners0.22%
Ins Owner Change18.28%
Market Cap415.40M
Analysts51.25
Price Target6.09 (32.68%)
Short Float %16.98%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.49%
Min EPS beat(2)-51.68%
Max EPS beat(2)126.66%
EPS beat(4)1
Avg EPS beat(4)-17.4%
Min EPS beat(4)-134.75%
Max EPS beat(4)126.66%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.07%
Min Revenue beat(2)-2.83%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-1.4%
Min Revenue beat(4)-5.76%
Max Revenue beat(4)4.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.04%
PT rev (3m)-47.59%
EPS NQ rev (1m)-0.68%
EPS NQ rev (3m)37.46%
EPS NY rev (1m)-1.26%
EPS NY rev (3m)5.55%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)2.3%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)0.79%
Valuation
Industry RankSector Rank
PE 11.48
Fwd PE 5.83
P/S 0.15
P/FCF 2.86
P/OCF 2.53
P/B 0.48
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.4
EY8.71%
EPS(NY)0.79
Fwd EY17.16%
FCF(TTM)1.6
FCFY34.93%
OCF(TTM)1.81
OCFY39.53%
SpS29.68
BVpS9.49
TBVpS-11.44
PEG (NY)0.28
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.32%
ROE -92.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.21%
FCFM 5.4%
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score5
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF 8.36
Debt/EBITDA N/A
Cap/Depr 23.04%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.97
Altman-Z 0.42
F-Score5
WACC6.83%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-543.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y40.94%
EPS Next 2Y52.2%
EPS Next 3Y46.84%
EPS Next 5Y41.59%
Revenue 1Y (TTM)-10.69%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%-1.63%
Revenue Next Year-6.93%
Revenue Next 2Y-3.07%
Revenue Next 3Y-0.94%
Revenue Next 5Y1.93%
EBIT growth 1Y-492.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.71%
EBIT Next 3Y9.38%
EBIT Next 5Y9.67%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A